{"id":870667,"date":"2025-08-05T07:11:28","date_gmt":"2025-08-05T11:11:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\/"},"modified":"2025-08-05T07:11:28","modified_gmt":"2025-08-05T11:11:28","slug":"ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\/","title":{"rendered":"AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <strong>AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt\">Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical development<\/li>\n<li style=\"margin-bottom:6pt\">ACI-7104.056 anti-alpha-synuclein active immunotherapy in Parkinson\u2019s disease produced strong immunogenicity and favorable safety profile in interim results from the ongoing Phase 2 VacSYn reported in April, with further data to come in H2 2025<\/li>\n<li style=\"margin-bottom:6pt\">Third Alzheimer\u2019s disease cohort (AD3) in the Phase 2 ABATE trial of anti-Abeta ACI-24.060 to reach 12 months of treatment in December 2025, with interim results expected early 2026<\/li>\n<li style=\"margin-bottom:6pt\">Small molecule NLRP3 program now in IND-enabling studies, highlighting promise in early-stage pipeline<\/li>\n<li style=\"margin-bottom:6pt\">Cash resources of CHF 127.1 million (USD157.6 million) as of June 30, 2025, provide funding into Q1 2027 excluding any potential milestone payments\n<\/li>\n<\/ul>\n<p>\n        <strong>Lausanne, Switzerland, August 5, 2025 &#8212; <\/strong>AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the quarter ended June 30, 2025, and provided a corporate update.<\/p>\n<p>\n        <strong>Dr. Andrea Pfeifer, CEO of AC Immune SA, commented:<\/strong> \u201cAC Immune is continuing to progress toward precision prevention of neurodegenerative diseases as we approach multiple value-inflection points through the rest of 2025 and beyond. Our industry symposium during the AD\/PD\u2122 conference focused on unlocking active immunotherapy for tailored prevention strategies highlighted the momentum of our three active immunotherapies in Phase 2 development. Interim results on ACI-7104.056, our wholly owned a-syn active immunotherapy, reinforced its best-in-class characteristics, showing strong immunogenicity and a favorable safety profile in early Parkinson\u2019s disease. The two partnered programs, ACI-24.060 and ACI-35.030, are also progressing according to plan. In addition, our Morphomer\u00ae small molecule drugs targeting a-syn and tau and Morphomer\u00ae-antibody drug conjugates (morADC) were featured in several presentations at AD\/PD\u2122 2025. In our exciting early-stage pipeline, ACI-19764, a novel Morphomer\u00ae small molecule inhibitor of NLRP3, has now entered studies to enable an Investigational New Drug (IND) filing.<\/p>\n<p>\u201cOur strong cash position provides funding into 2027, excluding potential milestone payments, and enables us to advance our robust pipeline focused on precision prevention of neurodegenerative diseases. Further interim results from Part 1 of the VacSYn trial of ACI-7104.056 are expected later this year, and the AD3 cohort in the ABATE trial of ACI-24.060 will reach 12 months of treatment around year end, with interim results thereafter. We also expect to file an IND for ACI-19764 this year.\u201d<\/p>\n<p>\n        <strong>Q2 2025 and Subsequent Highlights:<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt\">Reported interim safety and positive immunogenicity data from the Phase 2 VacSYn clinical trial evaluating ACI-7104.056, AC Immune\u2019s wholly owned anti-a-syn active immunotherapy candidate, for the treatment of patients with early PD.\n<ul type=\"circle\">\n<li style=\"margin-bottom:6pt\">As presented at <a href=\"https:\/\/ir.acimmune.com\/events\/event-details\/adpdtm-2025-symposium\" rel=\"nofollow\" target=\"_blank\">AD\/PD\u2122 2025<\/a>, treatment with ACI-7104.056 induced an average 20-fold increase in anti-a-syn antibodies after four immunizations compared to placebo background level.<\/li>\n<li style=\"margin-bottom:6pt\">Based on pharmacodynamic and biomarker interim results to be reported later this year, AC Immune may decide to initiate Part 2 of VacSYn, with the aim of establishing early proof-of-concept and identification of disease-specific biomarkers for rapid transition into a pivotal study.<\/li>\n<\/ul>\n<\/li>\n<li style=\"margin-bottom:6pt\">AC Immune\u2019s therapeutic and diagnostic programs were featured in <a href=\"https:\/\/www.acimmune.com\/our-science\/scientific-publications\/#conference-presentations\" rel=\"nofollow\" target=\"_blank\">multiple presentations at AD\/PD\u2122 2025<\/a>.<\/li>\n<li style=\"margin-bottom:6pt\">AC Immune hosted an <a href=\"https:\/\/ir.acimmune.com\/events\/event-details\/adpdtm-2025-symposium\" rel=\"nofollow\" target=\"_blank\">industry symposium<\/a> highlighting the company\u2019s industry-leading pipeline of active immunotherapies for precision prevention of neurodegenerative diseases.\n<\/li>\n<\/ul>\n<p>\n        <strong>Anticipated 2025 Milestones<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Program<\/strong>\n          <\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Milestone<\/strong>\n          <\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Expected in<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">ACI-24.060<br \/>anti-Abeta active immunotherapy<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">ABATE Phase 2 trial reaches 12-month treatment timepoint in the AD3 cohort by year end (with interim results reported thereafter)<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">H2 2025<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">ACI-7104.056<br \/>anti-a-syn active immunotherapy<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Interim pharmacodynamic and biomarker results from Part 1 of Phase 2 VacSYn trial in PD<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">H2 2025<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">ACI-19764<br \/>Small molecule NLRP3 inhibitor<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">IND\/CTA filing<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">H2 2025<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">TDP-43<br \/>monoclonal antibody<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Validated pharmacodynamic assay for clinical readout<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">H2 2025<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Morphomer-Tau aggregation inhibitors<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Lead declaration and initiation of IND-enabling studies<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">H2 2025<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Morphomer a-syn aggregation inhibitor<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Lead declaration<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">H2 2025<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">TDP-43-PET tracer<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Initial Phase 1 readout<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">H2 2025<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">ACI-15916<br \/>a-syn-PET tracer<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Phase 1 readout in Parkinson\u2019s disease (PD)<\/td>\n<td style=\"width:0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">H2 2025<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong><br \/>\n          <br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>Analysis of Financial Statements for the Quarter Ended June 30, 2025<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:6pt;text-align:justify\">\n          <strong>Cash Position:<\/strong> The Company had a total cash balance of CHF 127.1 million (CHF 165.5 million as of December 31, 2024), composed of CHF 25.7 million in cash and cash equivalents and CHF 101.4 million in short-term financial assets. The Company\u2019s cash balance provides sufficient capital resources into Q1 2027, excluding potential milestone payments.<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">\n          <strong>Contract Revenues: <\/strong>The Company recorded CHF 1.3 million in contract revenues for the three months ended June 30, 2025, compared to CHF 0.7 million in the comparable prior period. For the three months ended June 30, 2025, our contract revenues of CHF 1.3 million were related to the efforts made under the agreement with Takeda.<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">\n          <strong>R&amp;D Expenditures:<\/strong> R&amp;D expenses for the three months ended June 30, 2025, were CHF 16.8 million compared to CHF 17.1 million in the comparable period in 2024. The decrease was primarily due to reduced activity in early-stage discovery programs, as well as lower expenses incurred on ACI-7104.056. These reductions were offset by higher costs in the Morphomer Inflammasome program (ACI-19764).<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">\n          <strong>G&amp;A Expenditures:<\/strong> G&amp;A expenses, in comparison to the comparable period in 2024, decreased by CHF 0.7 million to CHF 3.9 million for the 3 months ended June, 30, 2025. The decrease was primarily driven by a decrease in legal fees related to business development and licensing activities which were executed in the prior period.<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">\n          <strong>IFRS Loss for the Period:<\/strong> The Company reported a net loss after taxes of CHF 21.2 million for the three months ended June 30, 2025, compared with a net loss of CHF 22.8 million for the comparable period in 2024.<\/p>\n<\/li>\n<\/ul>\n<p>\n        <strong>About\u00a0AC Immune SA\u00a0<\/strong><br \/>\n        <br \/>AC Immune SA\u00a0is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer\u2019s disease, Parkinson\u2019s disease, and NeuroOrphan indications driven by misfolded proteins. The Company\u2019s two clinically validated technology platforms, SupraAntigen\u00ae and Morphomer\u00ae, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development.\u00a0AC Immune\u00a0has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and &gt;$4.5 billion\u00a0in potential milestone payments plus royalties.<\/p>\n<p>SupraAntigen\u00ae is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer\u00ae is a registered trademark of AC Immune SA in CN, CH, EU, GB, JP, KR, NO, RU and SG.<\/p>\n<p>The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.<\/p>\n<p>\n        <strong>For further information, please contact:<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:490pt;border-collapse:collapse\">\n<tr>\n<td style=\"width:306.4px;vertical-align: top\">\n            <strong>SVP,\u00a0Investor Relations\u00a0&amp; Corporate Communications<\/strong><\/p>\n<p>Gary Waanders, Ph.D., MBA<br \/>AC Immune<br \/>Phone: +41 21 345 91 91<br \/>Email:\u00a0<a href=\"mailto:gary.waanders@cimmune.com\" rel=\"nofollow\" target=\"_blank\">gary.waanders@acimmune.com<\/a><\/p>\n<\/td>\n<td style=\"width:346.94px;vertical-align: top\">\n<p>            <strong>\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:320px\">\n            <strong>International Media<\/strong><\/p>\n<p>Chris Maggos<br \/>Cohesion Bureau<br \/>Phone: +41 79 367 6254<br \/>Email:\u00a0<a href=\"mailto:chris.maggos@cohesionbureau.com\" rel=\"nofollow\" target=\"_blank\">chris.maggos@cohesionbureau.com<\/a><\/td>\n<td style=\"width:346.94px;vertical-align: top\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>Forward looking statements<\/strong>\n      <\/p>\n<p>\n        <br \/>This press release contains statements that constitute \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune\u2019s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cprojects,\u201d \u201cpotential,\u201d \u201coutlook\u201d or \u201ccontinue,\u201d and other comparable terminology. Forward-looking statements are based on management\u2019s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions \u201cItem 3. Key Information \u2013 Risk Factors\u201d and \u201cItem 5. Operating and Financial Review and Prospects\u201d in AC Immune\u2019s Annual Report on Form 20-F and other filings with the\u00a0Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and\u00a0AC Immune\u00a0does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.<\/p>\n<p align=\"center\">\n        <strong><br \/>\n          <br \/>\n        <\/strong>\n      <\/p>\n<p align=\"center\">\n        <strong>Condensed Consolidated Balance Sheets (Unaudited)<\/strong><br \/>\n        <br \/>\n        <strong>(In CHF thousands)<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"width:13.94%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>As\u00a0of<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0\u00a0\u00a0\u00a0<\/strong>\n          <\/td>\n<td style=\"width:6.41%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>June\u00a030,\u00a0<\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0\u00a0\u00a0\u00a0<\/strong>\n          <\/td>\n<td style=\"width:6.41%;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>December\u00a031,\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2025<\/strong>\n          <\/td>\n<td style=\"width:1.11%;text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2024<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\n            <strong>Assets<\/strong>\n          <\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0\u00a0<\/strong>\n          <\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>\u00a0\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\n            <strong>Non-current assets<\/strong>\n          <\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0\u00a0<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Property, plant and equipment<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,490<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,651<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Right-of-use assets<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">4,926<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">5,437<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Intangible asset<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">50,416<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">50,416<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Long-term financial assets<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">584<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">415<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\n            <strong>Total non-current assets<\/strong>\n          <\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">58,416<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">58,919<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\n            <strong>Current assets<\/strong>\n          <\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Prepaid expenses<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,542<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">4,302<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Accrued income<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">510<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,099<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Other current receivables<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,621<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">1,104<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Short-term financial assets<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">101,413<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">129,214<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Cash and cash equivalents<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">25,722<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">36,275<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\n            <strong>Total current assets<\/strong>\n          <\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">131,808<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">171,994<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\n            <strong>Total assets <\/strong>\n          <\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">190,224<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">230,913<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\n            <strong>Shareholders&#8217; equity and liabilities<\/strong>\n          <\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\n            <strong>Shareholders\u2019 equity<\/strong>\n          <\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Share capital<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,236<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,226<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Share premium<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">479,680<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">478,506<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Treasury shares<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">(218)<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">(218)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Currency translation differences<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">4<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">(5)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Accumulated losses<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(406,959)<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">(368,239)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\n            <strong>Total shareholders\u2019 equity<\/strong>\n          <\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">74,743<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">112,270<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\n            <strong>Non-current liabilities<\/strong>\n          <\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Long-term deferred contract revenue<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">3,596<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">4,560<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Long-term lease liabilities<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">3,880<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">4,401<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Net employee defined benefit liabilities<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">9,036<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">8,844<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\n            <strong>Total non-current liabilities<\/strong>\n          <\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">16,512<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">17,805<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\n            <strong>Current liabilities<\/strong>\n          <\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Trade and other payables<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,729<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">2,658<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Accrued expenses<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">11476<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">12098<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Short-term deferred contract revenue<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">83,725<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;text-align: right;vertical-align: middle;vertical-align: bottom\">85,056<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: bottom\">Short-term lease liabilities<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">1,039<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">1,026<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\n            <strong>Total current liabilities<\/strong>\n          <\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">98,969<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">100,838<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\n            <strong>Total liabilities<\/strong>\n          <\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">115,481<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: bottom\">118,643<\/td>\n<\/tr>\n<tr>\n<td style=\"width:34.95%;vertical-align: bottom\">\n            <strong>Total shareholders\u2019 equity and liabilities<\/strong>\n          <\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">190,224<\/td>\n<td style=\"width:1.11%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"width:6.41%;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: bottom\">230,913<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\">\n        <strong><br \/>\n          <br \/>\n        <\/strong>\n      <\/p>\n<p align=\"center\">\n        <strong>Condensed Consolidated Statements of Income\/(Loss) (Unaudited)<\/strong><br \/>\n        <br \/>(<strong>In CHF thousands, except for per-share data)<\/strong><\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:498.67px;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"2\" rowspan=\"2\" style=\"width:173.34px;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>For the Three Months Ended June 30,\u00a0<\/strong><br \/>\n            \n          <\/td>\n<td style=\"width:32px;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"2\" rowspan=\"2\" style=\"width:173.34px;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>For the Six Months Ended June\u00a030,\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:498.67px;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:32px;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:498.67px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:86.67px;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>2025<\/strong>\n          <\/td>\n<td style=\"width:86.67px;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>2024<\/strong>\n          <\/td>\n<td style=\"width:32px;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:86.67px;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>2025<\/strong>\n          <\/td>\n<td style=\"width:86.67px;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>2024<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;vertical-align: middle\">\n            <strong>Revenue<\/strong>\n          <\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\n            <strong>\u00a0\u00a0<\/strong>\n          <\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\n            <strong>\u00a0\u00a0<\/strong>\n          <\/td>\n<td style=\"width:0px;vertical-align: middle\">\n            <strong>\u00a0\u00a0\u00a0\u00a0<\/strong>\n          <\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\n            <strong>\u00a0\u00a0<\/strong>\n          <\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\n            <strong>\u00a0\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;vertical-align: middle\">Contract revenue<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">1,306<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">687<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">2,296<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">687<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;vertical-align: middle\">\n            <strong>Total revenue<\/strong>\n          <\/td>\n<td style=\"width:0px;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: middle\">1,306<\/td>\n<td style=\"width:0px;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: middle\">687<\/td>\n<td style=\"width:0px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: middle\">2,296<\/td>\n<td style=\"width:0px;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: middle\">687<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;vertical-align: middle\">\n            <strong>Operating expenses<\/strong>\n          <\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:0px;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;vertical-align: middle\">Research &amp; development expenses<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">(16,826)<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">(17,138)<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">(32,742)<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">(32,303)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;vertical-align: middle\">General &amp; administrative expenses<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">(3,896)<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">(4,551)<\/td>\n<td style=\"width:0px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">(8,334)<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">(9,522)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;vertical-align: middle\">Other operating income\/(expense), net<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">28<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">41<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">21<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">109<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;vertical-align: middle\">\n            <strong>Total operating expenses<\/strong>\n          <\/td>\n<td style=\"width:0px;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: middle\">(20,694)<\/td>\n<td style=\"width:0px;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: middle\">(21,648)<\/td>\n<td style=\"width:0px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: middle\">(41,055)<\/td>\n<td style=\"width:0px;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: middle\">(41,716)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;vertical-align: middle\">\n            <strong>Operating loss<\/strong>\n          <\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">(19,388)<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">(20,961)<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">(38,759)<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">(41,029)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;vertical-align: middle\">Financial income<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">458<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">739<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">1,145<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">1,368<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;vertical-align: middle\">Financial expense<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">(50)<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">(34)<\/td>\n<td style=\"width:0px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">(103)<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">(70)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;vertical-align: middle\">Exchange differences<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">(2,209)<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">(2,504)<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">(2,501)<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">(891)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;vertical-align: middle\">\n            <strong>Finance result, net<\/strong>\n          <\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">(1,801)<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">(1,799)<\/td>\n<td style=\"width:0px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">(1,459)<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">407<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;vertical-align: middle\">\n            <strong>Loss before tax<\/strong>\n          <\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">(21,189)<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">(22,760)<\/td>\n<td style=\"width:0px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">(40,218)<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">(40,622)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;vertical-align: middle\">Income tax expense<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">\u2014<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;vertical-align: middle\">\n            <strong>Loss for the period<\/strong>\n          <\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">(21,189)<\/td>\n<td style=\"width:0px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">(22,760)<\/td>\n<td style=\"width:0px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: middle\">(40,218)<\/td>\n<td style=\"width:0px;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: middle\">(40,622)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;vertical-align: middle\">Loss per share:<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:0px;vertical-align: middle\">Basic and diluted loss per share for the period attributable<br \/>to equity holders<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">(0.21)<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">(0.23)<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">(0.4)<\/td>\n<td style=\"width:0px;text-align: right;vertical-align: middle;vertical-align: middle\">(0.41)<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\">\n        <strong><br \/>\n          <br \/>\n        <\/strong>\n      <\/p>\n<p align=\"center\">\n        <strong>Condensed Consolidated Statements of Comprehensive Income\/(Loss) (Unaudited)<\/strong><br \/>\n        <br \/>\n        <strong>(In CHF thousands)<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:351.6px;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"2\" rowspan=\"2\" style=\"width:116.6px;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>For the Three Months Ended June 30,\u00a0<\/strong><br \/>\n            \n          <\/td>\n<td style=\"width:23.8px;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td colspan=\"2\" rowspan=\"2\" style=\"width:109.74px;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>For the Six Months Ended June\u00a030,<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:351.6px;text-align: center;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:23.8px;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:351.6px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:54.94px;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>2025<\/strong>\n          <\/td>\n<td style=\"width:61.67px;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>2024<\/strong>\n          <\/td>\n<td style=\"width:23.8px;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"width:54.87px;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>2025<\/strong>\n          <\/td>\n<td style=\"width:54.87px;border-top: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: middle\">\n            <strong>2024<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:351.6px;vertical-align: middle\">Loss for the period<\/td>\n<td style=\"width:54.94px;vertical-align: middle;text-align: right;vertical-align: middle\">(21,189)<\/td>\n<td style=\"width:61.67px;text-align: right;vertical-align: middle;vertical-align: middle\">(22,760)<\/td>\n<td style=\"width:23.8px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:54.87px;text-align: right;vertical-align: middle;vertical-align: middle\">(40,218)<\/td>\n<td style=\"width:54.87px;text-align: right;vertical-align: middle;vertical-align: middle\">(40,622)<\/td>\n<\/tr>\n<tr>\n<td style=\"width:351.6px;vertical-align: middle\">Items that will be reclassified to income or loss in<br \/>subsequent periods (net of tax):<\/td>\n<td style=\"width:54.94px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:61.67px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:23.8px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:54.87px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:54.87px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:351.6px;vertical-align: middle\">Currency translation differences<\/td>\n<td style=\"width:54.94px;text-align: right;vertical-align: middle;vertical-align: middle\">4<\/td>\n<td style=\"width:61.67px;text-align: right;vertical-align: middle;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:23.8px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:54.87px;text-align: right;vertical-align: middle;vertical-align: middle\">9<\/td>\n<td style=\"width:54.87px;text-align: right;vertical-align: middle;vertical-align: middle\">16<\/td>\n<\/tr>\n<tr>\n<td style=\"width:351.6px;vertical-align: middle\">Items that will not to be reclassified to income or loss in subsequent periods (net of tax):<\/td>\n<td style=\"width:54.94px;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:61.67px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:23.8px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:54.87px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:54.87px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"width:351.6px;vertical-align: middle\">Remeasurement gains on defined-benefit plans (net of tax)<\/td>\n<td style=\"width:54.94px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:61.67px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:23.8px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:54.87px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:54.87px;border-bottom: solid black 1pt;text-align: right;vertical-align: middle;vertical-align: middle\">\u2014<\/td>\n<\/tr>\n<tr>\n<td style=\"width:351.6px;vertical-align: middle\">Other comprehensive income\/(loss)<\/td>\n<td style=\"width:54.94px;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: middle\">4<\/td>\n<td style=\"width:61.67px;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: middle\">\u2014<\/td>\n<td style=\"width:23.8px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:54.87px;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: middle\">9<\/td>\n<td style=\"width:54.87px;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: middle\">16<\/td>\n<\/tr>\n<tr>\n<td style=\"width:351.6px;vertical-align: middle\">\n            <strong>Total comprehensive loss, net of tax <\/strong>\n          <\/td>\n<td style=\"width:54.94px;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: middle\">(21,185)<\/td>\n<td style=\"width:61.67px;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: middle\">(22,760)<\/td>\n<td style=\"width:23.8px;text-align: right;vertical-align: middle;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:54.87px;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: middle\">(40,209)<\/td>\n<td style=\"width:54.87px;border-bottom: double black 3pt;text-align: right;vertical-align: middle;vertical-align: middle\">(40,606)<\/td>\n<\/tr>\n<\/table>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/5ec2b29c-02cb-499f-9eee-ca2b56688b8a\">20250805__ACIU 2Q25 Earnings PR_Final<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEyMTQ1NCM0MDIxOTQxMTMjMjAyNTg3MQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/MjQyMGI5ZDMtZjlmYi00OGI1LWFmOTctMzNhNTEzMTYyODc1LTEwMzc0NDMtMjAyNS0wOC0wNS1lbg==\/tiny\/AC-Immune-SA.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical development ACI-7104.056 anti-alpha-synuclein active immunotherapy in Parkinson\u2019s disease produced strong immunogenicity and favorable safety profile in interim results from the ongoing Phase 2 VacSYn reported in April, with further data to come in H2 2025 Third Alzheimer\u2019s disease cohort (AD3) in the Phase 2 ABATE trial of anti-Abeta ACI-24.060 to reach 12 months of treatment in December 2025, with interim results expected early 2026 Small molecule NLRP3 program now in IND-enabling studies, highlighting promise in early-stage pipeline Cash resources of CHF 127.1 million (USD157.6 million) as of June 30, 2025, provide funding into Q1 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-870667","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical development ACI-7104.056 anti-alpha-synuclein active immunotherapy in Parkinson\u2019s disease produced strong immunogenicity and favorable safety profile in interim results from the ongoing Phase 2 VacSYn reported in April, with further data to come in H2 2025 Third Alzheimer\u2019s disease cohort (AD3) in the Phase 2 ABATE trial of anti-Abeta ACI-24.060 to reach 12 months of treatment in December 2025, with interim results expected early 2026 Small molecule NLRP3 program now in IND-enabling studies, highlighting promise in early-stage pipeline Cash resources of CHF 127.1 million (USD157.6 million) as of June 30, 2025, provide funding into Q1 &hellip; Continue reading &quot;AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-05T11:11:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEyMTQ1NCM0MDIxOTQxMTMjMjAyNTg3MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update\",\"datePublished\":\"2025-08-05T11:11:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\\\/\"},\"wordCount\":1590,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEyMTQ1NCM0MDIxOTQxMTMjMjAyNTg3MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\\\/\",\"name\":\"AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEyMTQ1NCM0MDIxOTQxMTMjMjAyNTg3MQ==\",\"datePublished\":\"2025-08-05T11:11:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEyMTQ1NCM0MDIxOTQxMTMjMjAyNTg3MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEyMTQ1NCM0MDIxOTQxMTMjMjAyNTg3MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\/","og_locale":"en_US","og_type":"article","og_title":"AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - Market Newsdesk","og_description":"AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical development ACI-7104.056 anti-alpha-synuclein active immunotherapy in Parkinson\u2019s disease produced strong immunogenicity and favorable safety profile in interim results from the ongoing Phase 2 VacSYn reported in April, with further data to come in H2 2025 Third Alzheimer\u2019s disease cohort (AD3) in the Phase 2 ABATE trial of anti-Abeta ACI-24.060 to reach 12 months of treatment in December 2025, with interim results expected early 2026 Small molecule NLRP3 program now in IND-enabling studies, highlighting promise in early-stage pipeline Cash resources of CHF 127.1 million (USD157.6 million) as of June 30, 2025, provide funding into Q1 &hellip; Continue reading \"AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-05T11:11:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEyMTQ1NCM0MDIxOTQxMTMjMjAyNTg3MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update","datePublished":"2025-08-05T11:11:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\/"},"wordCount":1590,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEyMTQ1NCM0MDIxOTQxMTMjMjAyNTg3MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\/","name":"AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEyMTQ1NCM0MDIxOTQxMTMjMjAyNTg3MQ==","datePublished":"2025-08-05T11:11:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEyMTQ1NCM0MDIxOTQxMTMjMjAyNTg3MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEyMTQ1NCM0MDIxOTQxMTMjMjAyNTg3MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ac-immune-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/870667","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=870667"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/870667\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=870667"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=870667"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=870667"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}